Table 3 Summary of planned dosimetric parameters and day-to-day dosimetric results
Variable | Value, median (range) | Wilcoxon P value |
|---|---|---|
Planned dosimetric quantities | ||
Breast PTV Eval | ||
D95% [%] | 97.73 (93.63–98.64) | – |
V90% [%] | 99.50 (95.50–100.00) | – |
V105% [%] | 0.10 (0.00–41.10) | – |
BODY | ||
V90% [cc] | 1174.64 (863.13–1698.72) | – |
V105% [cc] | 3.67 (0.00–390.63) | – |
Global max dose [%] | 105.59 (104.94–106.92) | – |
Daily dosimetric quantities | ||
Breast PTV Eval | ||
D95% [%] | 97.74 (82.56–99.51)a | N.S |
V90% [%] | 99.30 (94.20–100.00)a | N.S |
V105% [%] | 13.15 (0.00–72.50)b | 1.5 × 10−4 |
BODY | ||
V90% [cc] | 1107.75 (831.38–1905.60) | – |
V105% [cc] | 130.45 (0.00–640.39)a,c | N.S |
Global max dose [%] | 108.85 (104.92–115.08)b | 4.4 × 10−16 |
Difference from prescribed (Δ) | ||
Breast PTV Eval | ||
ΔD95% [%] | − 0.04 (− 11.07 to 1.78) | N.S |
ΔV90% [%] | − 0.10 (− 1.70 to 0.20)* | 6.1 × 10−11 |
ΔV105% [%] | + 10.10 (− 15.40 to 72.50)* | 6.3 × 10−16 |
BODY | ||
ΔV90% [cc] | − 18.07 (− 155.14 to 206.87)* | 3.4 × 10−3 |
ΔV105% [cc] | + 92.40 (− 120.24 to 596.96)* | 9.4 × 10−18 |
ΔGlobal max dose [%] | + 2.43 (− 3.02 to 6.59)* | 6.7 × 10−17 |